Context Therapeutics CEO Marty Lehr joined Proactive's Natalie Stoberman to announce two clinical responses from its Phase 2 OATH Clinical Trial.

Lehr said two patients have achieved a confirmed partial response among the first 12 patients enrolled in the trial evaluating the potential of ONA-XR in combination with anastrozole to treat hormone receptor-positive metastatic endometrial cancer.

The findings are encouraging as ONA-XR exhibits initial signals of clinical activity and confirmed tumor shrinkage, Lehr added.

Contact Details

Proactive Investors USA

+1 347-449-0879

This email address is being protected from spambots. You need JavaScript enabled to view it.